Ascendis Pharma A/S Company Profile (NASDAQ:ASND)

About Ascendis Pharma A/S (NASDAQ:ASND)

Ascendis Pharma A/S logoAscendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ASND
  • CUSIP: N/A
  • Web: www.ascendispharma.com
Capitalization:
  • Market Cap: $787.52 million
  • Outstanding Shares: 32,502,000
Average Prices:
  • 50 Day Moving Avg: $27.66
  • 200 Day Moving Avg: $24.61
  • 52 Week Range: $11.92 - $31.86
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.55
  • P/E Growth: -0.31
Sales & Book Value:
  • Annual Revenue: $4.06 million
  • Price / Sales: 193.97
  • Book Value: $5.20 per share
  • Price / Book: 4.66
Profitability:
  • EBIDTA: ($84,980,000.00)
  • Net Margins: -1,158.57%
  • Return on Equity: -65.92%
  • Return on Assets: -58.86%
Debt:
  • Current Ratio: 6.52%
  • Quick Ratio: 6.52%
Misc:
  • Average Volume: 35,931 shs.
  • Beta: 0.22
  • Short Ratio: 8.8
 

Frequently Asked Questions for Ascendis Pharma A/S (NASDAQ:ASND)

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) released its quarterly earnings results on Tuesday, May, 23rd. The company reported ($0.83) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by $0.19. The business earned $0.40 million during the quarter, compared to analyst estimates of $1.10 million. Ascendis Pharma A/S had a negative net margin of 1,158.57% and a negative return on equity of 65.92%. View Ascendis Pharma A/S's Earnings History.

Where is Ascendis Pharma A/S's stock going? Where will Ascendis Pharma A/S's stock price be in 2017?

5 brokers have issued 12 month price objectives for Ascendis Pharma A/S's stock. Their predictions range from $26.00 to $36.00. On average, they anticipate Ascendis Pharma A/S's stock price to reach $31.00 in the next year. View Analyst Ratings for Ascendis Pharma A/S.

What are analysts saying about Ascendis Pharma A/S stock?

Here are some recent quotes from research analysts about Ascendis Pharma A/S stock:

  • 1. According to Zacks Investment Research, "Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. " (5/24/2017)
  • 2. Wedbush analysts commented, "The Wedbush View. We see ASND as an attractive investment in the short- and longer-term with pipeline progress and competitor data release in the coming months, plus results from the pivotal heiGHt trial in late 2018. Cash runway into Q4:18. Ascendis reported revenues of €0.37MM and a (loss) of €(0.78)." (5/24/2017)
  • 3. Leerink Swann analysts commented, "We project that ASND’s cash position at YE16 will be ~ $180M and expect this will fund operations through completion of its TransCon Growth Hormone study in 2018." (12/1/2016)

Are investors shorting Ascendis Pharma A/S?

Ascendis Pharma A/S saw a drop in short interest in the month of April. As of April 13th, there was short interest totalling 341,859 shares, a drop of 19.2% from the March 31st total of 423,134 shares. Based on an average daily trading volume, of 37,240 shares, the short-interest ratio is currently 9.2 days.

Who are some of Ascendis Pharma A/S's key competitors?

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Who owns Ascendis Pharma A/S stock?

Ascendis Pharma A/S's stock is owned by a variety of of institutional and retail investors. Top institutional investors include RA Capital Management LLC (16.69%), FMR LLC (0.00%), EcoR1 Capital LLC (3.16%), VHCP Management II LLC (0.00%), Janus Capital Management LLC (1.72%) and OppenheimerFunds Inc. (0.00%). View Institutional Ownership Trends for Ascendis Pharma A/S.

Who sold Ascendis Pharma A/S stock? Who is selling Ascendis Pharma A/S stock?

Ascendis Pharma A/S's stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC, Sphera Funds Management LTD., Janus Capital Management LLC, Emory University, Highbridge Capital Management LLC and Wells Fargo & Company MN. View Insider Buying and Selling for Ascendis Pharma A/S.

Who bought Ascendis Pharma A/S stock? Who is buying Ascendis Pharma A/S stock?

Ascendis Pharma A/S's stock was acquired by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Marshall Wace North America L.P., MARSHALL WACE ASIA Ltd, VHCP Management II LLC, FMR LLC, EcoR1 Capital LLC, Eventide Asset Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Ascendis Pharma A/S.

How do I buy Ascendis Pharma A/S stock?

Shares of Ascendis Pharma A/S can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ascendis Pharma A/S stock cost?

One share of Ascendis Pharma A/S stock can currently be purchased for approximately $24.23.

Analyst Ratings

Consensus Ratings for Ascendis Pharma A/S (NASDAQ:ASND) (?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $31.00 (27.94% upside)

Analysts' Ratings History for Ascendis Pharma A/S (NASDAQ:ASND)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/27/2017ValuEngineUpgradeSell -> HoldN/AView Rating Details
5/25/2017Leerink SwannLower Price TargetMarket Perform$30.00 -> $26.00LowView Rating Details
5/24/2017WedbushReiterated RatingOutperform$36.00 -> $34.00LowView Rating Details
5/11/2017JPMorgan Chase & Co.Initiated CoverageOverweight$36.00LowView Rating Details
2/9/2017Credit Suisse Group AGInitiated CoverageOutperform$28.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Ascendis Pharma A/S (NASDAQ:ASND)
Earnings by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)
Earnings History by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/23/2017Q1($0.64)($0.83)$1.10 million$0.40 millionViewN/AView Earnings Details
3/22/2017Q4($0.61)($0.55)$1.22 million$1.13 millionViewN/AView Earnings Details
11/30/2016Q316($0.71)($0.80)$1.25 million$1.30 millionViewN/AView Earnings Details
8/31/2016Q216($0.67)($0.60)$1.11 million$1.28 millionViewListenView Earnings Details
5/19/2016Q1($0.55)($0.90)$1.39 millionViewN/AView Earnings Details
4/14/2016Q4 2015($0.46)($0.54)$2.17 millionViewN/AView Earnings Details
8/24/2015Q2($0.48)($0.70)$2.23 million$2.15 millionViewN/AView Earnings Details
5/18/2015Q115($0.39)$0.07$2.24 million$2.38 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ascendis Pharma A/S (NASDAQ:ASND)
2017 EPS Consensus Estimate: ($3.10)
2018 EPS Consensus Estimate: ($3.39)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.68)($0.68)($0.68)
Q2 20172($0.82)($0.79)($0.81)
Q3 20172($0.82)($0.79)($0.81)
Q4 20172($0.83)($0.79)($0.81)
Q1 20181($0.83)($0.83)($0.83)
Q2 20181($0.84)($0.84)($0.84)
Q3 20181($0.85)($0.85)($0.85)
Q4 20181($0.87)($0.87)($0.87)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ascendis Pharma A/S (NASDAQ:ASND)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ascendis Pharma A/S (NASDAQ:ASND)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Ascendis Pharma A/S (NASDAQ:ASND)
Latest Headlines for Ascendis Pharma A/S (NASDAQ:ASND)
Source:
DateHeadline
americanbankingnews.com logoAscendis Pharma A/S (ASND) Price Target Cut to $26.00 by Analysts at Leerink Swann
www.americanbankingnews.com - May 27 at 6:22 PM
americanbankingnews.com logoAscendis Pharma A/S (ASND) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - May 27 at 3:50 PM
americanbankingnews.com logoQ2 2017 EPS Estimates for Ascendis Pharma A/S Increased by Leerink Swann (ASND)
www.americanbankingnews.com - May 26 at 8:00 AM
americanbankingnews.com logoAscendis Pharma A/S Forecasted to Earn Q2 2017 Earnings of ($0.82) Per Share (ASND)
www.americanbankingnews.com - May 26 at 8:00 AM
americanbankingnews.com logoAscendis Pharma A/S (ASND) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 24 at 5:46 PM
americanbankingnews.com logoAscendis Pharma A/S (ASND) Given Buy Rating at Wedbush
www.americanbankingnews.com - May 24 at 4:32 PM
americanbankingnews.com logoAscendis Pharma A/S (ASND) Issues Earnings Results, Misses Estimates By $0.19 EPS
www.americanbankingnews.com - May 24 at 10:34 AM
finance.yahoo.com logoAscendis Pharma A/S Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 24 at 9:30 AM
americanbankingnews.com logo$1.1 Million in Sales Expected for Ascendis Pharma A/S (ASND) This Quarter
www.americanbankingnews.com - May 21 at 3:08 PM
americanbankingnews.com logoAscendis Pharma A/S (ASND) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 16 at 5:16 PM
americanbankingnews.com logoAscendis Pharma A/S (ASND) Expected to Post Earnings of -$0.64 Per Share
www.americanbankingnews.com - May 16 at 8:26 AM
americanbankingnews.com logoAscendis Pharma A/S (ASND) Now Covered by Analysts at JPMorgan Chase & Co.
www.americanbankingnews.com - May 14 at 8:46 AM
bizjournals.com logoMacrophage Pharma Appoints Development Director
www.bizjournals.com - May 11 at 4:06 PM
finance.yahoo.com logoAscendis Pharma A/S Announces First Quarter 2017 Financial Results Conference Call on May 23
finance.yahoo.com - May 11 at 4:06 PM
americanbankingnews.com logoAscendis Pharma A/S (ASND) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 11 at 9:16 AM
americanbankingnews.com logoAscendis Pharma A/S (ASND) Receives News Impact Rating of 0.06
www.americanbankingnews.com - May 2 at 12:20 PM
americanbankingnews.com logoAscendis Pharma A/S (ASND) Earning Somewhat Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - April 29 at 9:56 AM
americanbankingnews.com logoAscendis Pharma A/S (ASND) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - April 28 at 9:14 PM
americanbankingnews.com logoAscendis Pharma A/S (ASND) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - April 28 at 9:14 PM
finance.yahoo.com logoAscendis Pharma A/S Announces Upcoming Investor Presentations
finance.yahoo.com - April 28 at 4:36 PM
americanbankingnews.com logoZacks: Brokerages Expect Ascendis Pharma A/S (ASND) to Announce -$0.64 EPS
www.americanbankingnews.com - April 25 at 4:08 PM
americanbankingnews.com logoAscendis Pharma A/S (ASND) Earns Daily Media Impact Rating of 0.07
www.americanbankingnews.com - April 25 at 12:32 PM
americanbankingnews.com logoAscendis Pharma A/S (ASND) Given Daily Coverage Optimism Rating of 0.04
www.americanbankingnews.com - April 21 at 10:45 AM
finance.yahoo.com logoAscendis Pharma A/S :ASND-US: Earnings Analysis: Q4, 2016 By the Numbers : April 20, 2017
finance.yahoo.com - April 20 at 3:45 PM
americanbankingnews.com logoAscendis Pharma A/S (ASND) Given Daily Media Impact Score of 0.16
www.americanbankingnews.com - April 17 at 2:04 PM
americanbankingnews.com logoAscendis Pharma A/S (ASND) Given Coverage Optimism Rating of 0.02
www.americanbankingnews.com - April 14 at 4:20 PM
americanbankingnews.com logo Ascendis Pharma A/S (ASND) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - April 13 at 6:28 PM
finance.yahoo.com logoAscendis Pharma A/S Showcases New Data on Rare Disease Product Pipeline at ENDO 2017
finance.yahoo.com - April 4 at 4:27 AM
americanbankingnews.com logoAscendis Pharma A/S (ASND) Rating Reiterated by Wedbush
www.americanbankingnews.com - April 3 at 12:43 PM
finance.yahoo.com logoAscendis Pharma A/S Announces Updated Time for April 3 Conference Call to Review ENDO 2017 Data
finance.yahoo.com - March 31 at 3:48 PM
americanbankingnews.com logoWedbush Raises Ascendis Pharma A/S (ASND) Price Target to $34.00
www.americanbankingnews.com - March 30 at 8:20 AM
finance.yahoo.com logoASCENDIS PHARMA A/S Financials
finance.yahoo.com - March 28 at 3:39 PM
americanbankingnews.com logoAnalysts Set Expectations for Ascendis Pharma A/S's Q1 2018 Earnings (ASND)
www.americanbankingnews.com - March 27 at 9:53 AM
americanbankingnews.com logoAscendis Pharma A/S (ASND) PT Raised to $34.00
www.americanbankingnews.com - March 24 at 3:37 PM
finance.yahoo.com logoAscendis Pharma A/S Announces Conference Call and Webcast to Review Data at ENDO 2017 on April 3
finance.yahoo.com - March 23 at 4:05 PM
americanbankingnews.com logo Analysts Set $31.67 Target Price for Ascendis Pharma A/S (ASND)
www.americanbankingnews.com - March 23 at 10:26 AM
finance.yahoo.com logoAscendis Pharma A/S Reports Full Year 2016 Financial Results
finance.yahoo.com - March 22 at 4:10 PM
finance.yahoo.com logoAscendis Pharma A/S Announces Year-End 2016 Financial Results Conference Call on March 22
finance.yahoo.com - March 10 at 4:27 PM
us.rd.yahoo.com logo4:50 pm Ascendis Pharma will present eight posters at the annual meeting of the Endocrine Society taking place April 1-4; remains on track for filing an IND or equivalent for TransCon PTH in the second quarter this year
us.rd.yahoo.com - March 1 at 8:40 PM
finance.yahoo.com logoAscendis Pharma A/S Announces Multiple Poster Presentations at ENDO 2017
finance.yahoo.com - March 1 at 5:57 AM
finance.yahoo.com logoAscendis Pharma A/S Announces Publication of Comprehensive Results from Randomized, Active-Controlled Phase 2 Trial of Once-Weekly TransCon Growth Hormone in Pediatric Patients
finance.yahoo.com - February 16 at 8:44 PM
finance.yahoo.com logoAscendis Pharma A/S Announces Publication of Comprehensive Results from Randomized, Active-Controlled Phase 2 Trial of Once-Weekly TransCon Growth Hormone in Pediatric Patients
finance.yahoo.com - February 16 at 8:44 PM
finance.yahoo.com logo4:07 pm Ascendis Pharma announces the publication of its previously presented pediatric phase 2 trial of TransCon Growth Hormone in the Journal of Clinical Endocrinology and Metabolism
finance.yahoo.com - February 16 at 8:44 PM
finance.yahoo.com logo4:07 pm Ascendis Pharma announces the publication of its previously presented pediatric phase 2 trial of TransCon Growth Hormone in the Journal of Clinical Endocrinology and Metabolism
finance.yahoo.com - February 16 at 8:44 PM
finance.yahoo.com logoAscendis (ASND) Catches Eye: Stock Gains 7.2% in Session
finance.yahoo.com - February 16 at 8:34 AM
us.rd.yahoo.com logoCoverage initiated on Ascendis Pharma by Credit Suisse
us.rd.yahoo.com - February 9 at 8:49 PM
finance.yahoo.com logoAscendis Pharma A/S Announces Presentation at the LEERINK Partners 6th Annual Global Healthcare Conference on February 15th
finance.yahoo.com - February 7 at 4:35 PM
finance.yahoo.com logoAscendis Pharma A/S Announces Presentation at 35th Annual J.P. Morgan Healthcare Conference on January 9
finance.yahoo.com - January 3 at 9:20 PM
finance.yahoo.com logoBlog Coverage Intercept Pharma Receives European Approval for the Treatment of a Rare Liver Condition
finance.yahoo.com - December 15 at 3:28 PM
finance.yahoo.com logoWhy Ascendis Pharma (ASND) Stock Might be a Great Pick
finance.yahoo.com - December 14 at 4:22 PM

Social

Chart

Ascendis Pharma A/S (ASND) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff